Oryzon Genomics Website, Blog & Press Pages

Oryzon Genomics Website, Blog & Press Pages - aVenture Research

Library

oryzon.comCrawled Nov 10, 2026

6 pages

Announcement of the Ordinary Shareholders' General Meeting/en/node/81
Epigenetics/en/epigenetics/epigenetics
Epigenetics involves gene expression changes without altering DNA sequence, influenced by biological processes, diet, and environmental factors.
LSD1/en/epigenetics/lsd1
LSD1 (KDM1A) is a histone-modifying enzyme that regulates gene expression linked to cancer, CNS disorders, and viral infections.
Pipeline/en/programs/pipeline
Oryzon Genomics is a clinical stage biopharmaceutical company that discovers, develops, and plans to commercialize novel epigenetic therapies to treat oncological/hematological disorders and CNS diseases.

2 pages

ORYZON Hosting Key Opinion Leader Webinar on Targeting Lysine Specific Demethylase 1 (LSD1) in CNS and Psychiatric Disorders and Oncology/en/news-events/news/oryzon-hosting-key-opinion-leader-webinar-targeting-lysine-specific-demethylase-1
Publications/en/programs/publications
Oryzon conducts cutting-edge epigenetics research, focusing on oncology and CNS. The company shares findings through peer-reviewed publications and international conferences.

6 pages

34th EORTC-NCI-AACR Symposium/en/news-events/events/34th-eortc-nci-aacr-symposium
Oryzon presented poster sessions on iadademstat’s effects in small cell lung cancer and AML at an October 2022 event.
BIO-Europe 2022/en/news-events/events/bio-europe-2022
Location: also virtual meeting
Kabuki Syndrome Foundation Annual Conference/en/news-events/events/kabuki-syndrome-foundation-annual-conference
Location: virtual meeting
ORYZON leads an Eurostars project to promote new epigenetic treatments/en/news-events/news/oryzon-leads-eurostars-project-promote-new-epigenetic-treatments
A consortium led by Oryzon received Eurostar funding for epigenetic treatments in oncology and neurodegenerative diseases.

1 page

Join Us/en/contact/join-us
Oryzon Genomics offers job opportunities and accepts applications through its website.

6 pages

Konstantinos Alataris/en/company/team/konstantinos-alataris
Dr. Alataris has over 30 years of experience in medical technology, founding and leading companies like Nēsos and Zosano Pharma.
Luis Sánchez Quintana/en/company/team/luis-sanchez-quintana
Mr. Sánchez Quintana is a former PwC partner with over 33 years of experience in pharmaceutical and biotech audits.
Montserrat Vendrell/en/company/team/montserrat-vendrell
Dr. Vendrell is a venture capital partner at Asabys Partners, former CEO of Biocat and Barcelona Science Park, and holds a PhD in biology.
Neus Virgili/en/company/team/neus-virgili
Qualified European Patent Attorney, with over 25 years experience as corporate patent attorney in the pharmaceutical field. B.Sc. in Organic Chemistry from the University of Barcelona, Spain.

6 pages

Collaborations/en/programs/collaborations
Oryzon collaborates with the research community to advance its epigenetic platform and product development.
Corporate Governance/en/investors/corporate-governance
This section provides downloadable documents, including the Articles of Association and Corporate Governance Reports.
Dr. Carlos Buesa, Oryzon Genomics CEO, to be a Keynote Speaker at the 15th Annual Global Discovery-Summit 2015 in Lisbon, Portugal/en/node/43
Oryzon’s CEO, Dr. Carlos Buesa, presented on epigenetic approaches for Alzheimer’s at the 15th Annual Global Discovery-Summit 2015.
Oryzon to Present at BioTrinity 2011 Conference in UK/en/node/75
Oryzon presented its epigenetic drug discovery program for neurodegenerative disorders at BioTrinity 2011.

2 pages

1 page

2 pages

Cookie Policy/en/cookie-policy
Oryzon Genomics provides a Cookies Policy outlining its data protection practices for website users.
Privacy Policy/en/privacy-policy

1 page